Antibody-based immunosuppressive agents for corneal transplantation.
The progress in antibody engineering over the last 20 years has created the tools for the development of novel antibody-based drugs and constructs, such as small antibody fragments, suitable for topical administration. In rheumatology, oncology, transplantation medicine and ophthalmology, therapeutic antibody constructs, and antibody fragments have been responsible for the clinical progress seen over the last decade. Although antibody-based therapies have become a well-established immunosuppressive option in solid organ transplantation, there are only very few reports with regard to corneal transplantation. The following review explains some of the important aspects of engineered antibody-based therapeutic agents and summarises the current use of such immunosuppressive therapies in transplantation medicine and corneal transplantation.
Thiel
M A
MA
Department of Ophthalmology, Cantonal Hospital Lucerne, 6000 Lucerne 16, Switzerland. Michael.Thiel@ksl.ch
Kaufmann
C
C
Coster
D J
DJ
Williams
K A
KA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016039:Corneal Transplantation / Q000379:methods*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents